about
Prothrombotic State in Asthma Is Related to Increased Levels of Inflammatory Cytokines, IL-6 and TNFα, in Peripheral Blood.Architecture of fibrin network inside thrombotic material obtained from the right atrium and pulmonary arteries: flow and location matter.Impaired fibrinolysis and lower levels of plasma α2-macroglobulin are associated with an increased risk of severe asthma exacerbations.Fibrin structure in organized thrombotic material removed during pulmonary artery endarterectormy: the effect of vessel calibreA fibrinogen concentrate Haemocomplettan (Riastap) or a Factor XIII concentrate Fibrogammin combined with a mini dose of tranexamic acid can reverse the fibrin instability to fibrinolysis induced by thrombin- or FXa-inhibitor.Asthma is associated with enhanced thrombin formation and impaired fibrinolysis.Vitamin K antagonists favourably modulate fibrin clot properties in patients with atrial fibrillation as early as after 3days of treatment: Relation to coagulation factors and thrombin generation.Plasma fibrin clot phenotype independently affects intracoronary thrombus ultrastructure in patients with acute myocardial infarction.Shotgun analysis of plasma fibrin clot-bound proteins in patients with acute myocardial infarction.Improvement of fibrin clot structure after factor VIII injection in haemophilia A patients treated on demand.Fibrinogen depletion after plasma-dilution: impairment of proteolytic resistance and reversal via clotting factor concentrates.Antithrombotic medications and their impact on fibrin clot structure and functionPolyhedrocytes in blood clots of type 2 diabetic patients with high cardiovascular risk: association with glycemia, oxidative stress and platelet activationDecreased Levels of Histidine-Rich Glycoprotein in Advanced Lung Cancer: Association with Prothrombotic AlterationsReduced plasma fibrin clot permeability is associated with recurrent thromboembolic events in patients with antiphospholipid syndromeThe effect of DOAC-Stop on lupus anticoagulant testing in plasma samples of venous thromboembolism patients receiving direct oral anticoagulants.Factors associated with the presence of circulating active tissue factor and activated factor XI in stable angina patientsCoronary thrombus composition: links with inflammation, platelet and endothelial markersPolyhedrocytes in intracoronary thrombi from patients with ST-elevation myocardial infarctionDOAC-Remove abolishes the effect of direct oral anticoagulants on activated protein C resistance testing in real-life venous thromboembolism patientsAltered structure and function of fibrinogen after cleavage by Factor VII Activating Protease (FSAP)Elevated Lactate Levels in Acute Pulmonary Embolism Are Associated with Prothrombotic Fibrin Clot Properties: Contribution of NETs FormationA Prothrombotic State in Patients With a History of Left Ventricular ThrombusAntiphosphatidylserine/prothrombin complex antibodies as a determinant of prothrombotic plasma fibrin clot properties in patients with antiphospholipid syndrome
P50
Q33862178-8AC1BE00-998A-4CD3-94ED-27A7EAFD286CQ36487656-3B9E0D51-5937-44FA-A8DD-88E6A2727230Q41476326-121CCCA7-5390-4B54-8D0E-5BB1BB51E519Q42632247-64AEE883-AC52-4D4B-BEDF-1BB1DC9500F9Q45973915-8CC2975B-1478-4B5E-8478-5118BA919E3FQ50682473-C73C4038-DA44-47AB-8EC8-426435CBCA24Q53367784-FA2119C3-B39D-4E18-B33B-C0C88A1C6840Q53594930-5E8FA5CB-A084-43CC-8E51-38C44F5F70ABQ53606951-5292E7B8-9AF7-4494-A820-B32EAF14D9BAQ54563713-B1062639-2CCC-4BC1-9CA0-8849C3DBDB75Q54653572-1C52630D-7351-4288-8727-E5C0D5977A02Q58567182-56E9A752-1776-4612-B76E-04BA5E46665EQ59329569-DFB8BA2A-5E06-433C-950D-C16AAF091DA0Q64070792-307D4B1B-3D1C-4947-9473-CE57282864D5Q64125110-59AA0766-E606-49C7-86A3-873D17AC706CQ67429071-3367F747-4394-46C0-9844-EA702A2A4BEBQ83463030-FECF69BF-147C-4700-876C-2E9F2CBE2FF0Q86156725-60959671-EE64-4339-B3B0-77558E95EC13Q86163997-170006F3-C9C8-4532-8475-5E5E29F31C66Q90190211-D82B54A8-7F11-4EC5-B72D-788E076A9BBAQ90751386-EA28D71E-0DE8-4693-8455-C65452C8EF1EQ90810091-06E82C11-3518-4AF8-99D4-A38027007BAAQ91338230-7D495A86-8B8E-412C-9C18-B7BBF958203DQ92905513-E6714348-9627-4385-9305-606442454520
P50
description
Polish researcher
@en
polski naukowiec
@pl
taighdeoir Polannach
@ga
wetenschapper
@nl
name
Michał Ząbczyk
@ast
Michał Ząbczyk
@ca
Michał Ząbczyk
@de
Michał Ząbczyk
@en
Michał Ząbczyk
@es
Michał Ząbczyk
@fr
Michał Ząbczyk
@ga
Michał Ząbczyk
@gl
Michał Ząbczyk
@it
Michał Ząbczyk
@nl
type
label
Michał Ząbczyk
@ast
Michał Ząbczyk
@ca
Michał Ząbczyk
@de
Michał Ząbczyk
@en
Michał Ząbczyk
@es
Michał Ząbczyk
@fr
Michał Ząbczyk
@ga
Michał Ząbczyk
@gl
Michał Ząbczyk
@it
Michał Ząbczyk
@nl
altLabel
Michal Zabczyk
@en
prefLabel
Michał Ząbczyk
@ast
Michał Ząbczyk
@ca
Michał Ząbczyk
@de
Michał Ząbczyk
@en
Michał Ząbczyk
@es
Michał Ząbczyk
@fr
Michał Ząbczyk
@ga
Michał Ząbczyk
@gl
Michał Ząbczyk
@it
Michał Ząbczyk
@nl
P214
P1153
37002405800
P1412
P1559
Michał Ząbczyk
@pl
P21
P214
P27
P31
P3124
P496
0000-0003-1762-308X
P735
P7859
viaf-317135587